CSIR-NCL AND DST SIGN AN AGREEMENT WITH LUPIN FOR THE DEVELOPMENT OF A CONTINUOUS MANUFACTURING PROCESS FOR BIOSIMILAR MONOCLONAL ANTIBODY THERAPEUTIC

摘要

CSIR-NCL and DST sign an agreement with Lupin for the development of a continuous manufacturing process for biosimilar monoclonal antibody therapeutic CSIR-National Chemical Laboratory (CSIR-NCL, Pune) and Department of Science and Technology (DST, New Delhi) signed a research collaboration agreement with Lupin Ltd. for a continuous purification process development of a biosimilar monoclonal antibody therapeutic. Monoclonal antibodies represent the most important biopharmaceutical product class, serving the highdemand treatment area of immuno-oncology diseases. With an increasing demand for biosimilar therapeutics and an ever-increasing pressure for manufacturing cost reduction with quality maintenance, the biopharmaceutical industry is showing keen interest in the development of continuous manufacturing processes. All unit operations in existing manufacturing processes are currently performed in a batch mode with an overall process recovery limiting to 40-50%.